These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 2574898)

  • 1. Choice of rating form for evaluating anxiolytics.
    Wang RI; Kochar C
    Psychopharmacol Bull; 1989; 25(2):291-5. PubMed ID: 2574898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of self-report assessment in studies of anxiety disorders.
    Glass RM; Uhlenhuth EH; Kellner R
    J Clin Psychopharmacol; 1987 Aug; 7(4):215-21. PubMed ID: 2887588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New anxiolytic drugs: methodological issues].
    Ginestet D; Corruble E
    Encephale; 1993; 19(6):627-37. PubMed ID: 12404782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A brief anxiety rating scale in evaluating anxiolytics.
    Wang RI; Wiesen RL; Treul S; Stockdale S
    J Clin Pharmacol; 1976; 16(2-3):99-105. PubMed ID: 3521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of bedtime dosing of benzodiazepines: a placebo-controlled comparison of halazepam and clorazepate.
    Aden GC; O'Hair DE
    Clin Ther; 1980; 3(3):209-18. PubMed ID: 6109568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions between anxiety, social support, health status and buspirone efficacy in elderly patients.
    Majercsik E; Haller J
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Nov; 28(7):1161-9. PubMed ID: 15610929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
    Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
    Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance of self-rated and observer-rated dysphoric symptoms in mania.
    Cassidy F; Ahearn E; Carroll BJ
    J Affect Disord; 2009 Apr; 114(1-3):294-8. PubMed ID: 18684512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE; Franznick DA; Hollander SB; Fava M
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of anxiety in outpatient trials: detection of bias in patient and doctor ratings.
    Fisher S
    Psychopharmacol Bull; 1976 Apr; 12(2):17-8. PubMed ID: 3818
    [No Abstract]   [Full Text] [Related]  

  • 11. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression.
    Bech P; Tanghøj P; Andersen HF; Overø K
    Psychopharmacology (Berl); 2002 Aug; 163(1):20-5. PubMed ID: 12185396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The influence of alprazolam on the symptoms of anxiety and depression].
    Małyszczak K; Kiejna A
    Psychiatr Pol; 1997; 31(6):745-52. PubMed ID: 9515306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emotional withdrawal, CT abnormalities and drug response in late life depression.
    Altamura AC; Bassetti R; Santini A; Frisoni GB; Mundo E
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):349-54. PubMed ID: 14751432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial.
    Feltner D; Hill C; Lenderking W; Williams V; Morlock R
    J Psychiatr Res; 2009 Oct; 43(15):1224-30. PubMed ID: 19423131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escitalopram in the treatment of anxiety symptoms associated with depression.
    Bandelow B; Andersen HF; Dolberg OT
    Depress Anxiety; 2007; 24(1):53-61. PubMed ID: 16937393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders.
    Lee JH; Dunner DL
    Depress Anxiety; 2008; 25(2):91-7. PubMed ID: 17311265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A method for evaluating anxiolytic sedatives.
    Wang RI; Wiesen RL; Stockdale S; Hieb E
    J Clin Pharmacol; 1977; 17(5-6):269-75. PubMed ID: 16039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alprazolam treatment of postcoronary bypass anxiety and depression.
    Freeman AM; Fleece L; Folks DG; Sokol RS; Hall KR; Pacifico AD; McGiffin DC; Kirklin JK; Zorn GL; Karp RB
    J Clin Psychopharmacol; 1986 Feb; 6(1):39-41. PubMed ID: 2869060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder.
    Meoni P; Hackett D; Lader M
    Depress Anxiety; 2004; 19(2):127-32. PubMed ID: 15022148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depressive symptoms and intellectual functioning in anxiety patients treated with clorazepate.
    Fabre LF; Putman HP
    J Clin Psychiatry; 1988 May; 49(5):189-92. PubMed ID: 2896666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.